Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $60.22

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $60.22.

A number of research firms have issued reports on CLDX. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. UBS Group initiated coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX traded up $0.49 during mid-day trading on Friday, hitting $23.03. 278,607 shares of the company's stock traded hands, compared to its average volume of 962,851. The company has a fifty day moving average of $24.63 and a 200 day moving average of $29.62. Celldex Therapeutics has a twelve month low of $20.91 and a twelve month high of $53.18. The company has a market capitalization of $1.53 billion, a P/E ratio of -8.96 and a beta of 1.60.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $38,919,000. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after buying an additional 1,167,659 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after buying an additional 847,264 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after buying an additional 676,771 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock valued at $45,017,000 after acquiring an additional 321,325 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.